

# UCLA

## UCLA Previously Published Works

### Title

Intense Arm Rehabilitation Therapy Improves the Modified Rankin Scale Score: Association Between Gains in Impairment and Function.

### Permalink

<https://escholarship.org/uc/item/4hs7z34g>

### Journal

Neurology, 96(14)

### ISSN

0028-3878

### Authors

Cramer, Steven C  
Le, Vu  
Saver, Jeffrey L  
et al.

### Publication Date

2021-04-06

### DOI

10.1212/wnl.00000000000011667

Peer reviewed

# Intense Arm Rehabilitation Therapy Improves the Modified Rankin Scale Score

## Association Between Gains in Impairment and Function

Steven C. Cramer, MD, Vu Le, MS, Jeffrey L. Saver, MD, Lucy Dodakian, MA, OTR/L, Jill See, PT, MPT, Renee Augsburg, OTR/L, Alison McKenzie, DPT, PhD, Robert J. Zhou, BA, Nina L. Chiu, BS, Jutta Heckhausen, PhD, Jessica M. Cassidy, DPT, PhD, Walt Scacchi, PhD, Megan Therese Smith, PhD, A.M. Barrett, MD, Jayme Knutson, PhD, Dylan Edwards, PhD, PT, David Putrino, PhD, PT, Kunal Agrawal, MD, Kenneth Ngo, MD, Elliot J. Roth, MD, David L. Tirschwell, MD, Michelle L. Woodbury, PhD, OTR/L, Ross Zafonte, DO, Wenle Zhao, PhD, Judith Spilker, BSN, RN, Steven L. Wolf, PT, PhD, Joseph P. Broderick, MD, and Scott Janis, PhD

### Correspondence

Dr. Cramer  
sccramer@mednet.ucla.edu

Neurology® 2021;96:e1812-e1822. doi:10.1212/WNL.0000000000011667

## Abstract

### Objective

To evaluate the effect of intensive rehabilitation on the modified Rankin Scale (mRS), a measure of activities limitation commonly used in acute stroke studies, and to define the specific changes in body structure/function (motor impairment) most related to mRS gains.

### Methods

Patients were enrolled >90 days poststroke. Each was evaluated before and 30 days after a 6-week course of daily rehabilitation targeting the arm. Activity gains, measured using the mRS, were examined and compared to body structure/function gains, measured using the Fugl-Meyer (FM) motor scale. Additional analyses examined whether activity gains were more strongly related to specific body structure/function gains.

### Results

At baseline (160 ± 48 days poststroke), patients (n = 77) had median mRS score of 3 (interquartile range, 2–3), decreasing to 2 [2–3] 30 days posttherapy (p < 0.0001). Similarly, the proportion of patients with mRS score ≤2 increased from 46.8% at baseline to 66.2% at 30 days posttherapy (p = 0.015). These findings were accounted for by the mRS score decreasing in 24 (31.2%) patients. Patients with a treatment-related mRS score improvement, compared to those without, had similar overall motor gains (change in total FM score, p = 0.63). In exploratory analysis, improvement in several specific motor impairments, such as finger flexion and wrist circumduction, was significantly associated with higher likelihood of mRS decrease.

### Conclusions

Intensive arm motor therapy is associated with improved mRS in a substantial fraction (31.2%) of patients. Exploratory analysis suggests specific motor impairments that might underlie this finding and may be optimal targets for rehabilitation therapies that aim to reduce activities limitations.

### RELATED ARTICLE

#### Editorial

Connecting Upper Limb Functional Stroke Recovery to Global Disability Measures: Finding the Forest in the Trees

Page 643

### MORE ONLINE

#### → Class of Evidence

Criteria for rating therapeutic and diagnostic studies

[NPub.org/coe](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC811667/)

From the Department of Neurology (S.C.C., J.L.S.), University of California, Los Angeles; California Rehabilitation Institute (S.C.C.), Los Angeles; Department of Neurology (S.C.C., V.L., L.D., J. See, R.A., A.M., R.J.Z., N.L.C., J.M.C.), Department of Psychological Science (J.H.), Institute for Software Research (W.S.), and Department of Statistics (M.T.S.), University of California, Irvine; Department of Physical Therapy (A.M.), Chapman University, Irvine, CA; Department of Allied Health Sciences (J.M.C.), University of North Carolina at Chapel Hill; Department of Stroke Rehabilitation Research (A.M.B.), Kessler Foundation; Department of Stroke Rehabilitation (A.M.B.), Kessler Institute for Rehabilitation, West Orange, NJ; Department of Physical Medicine and Rehabilitation (J.K.), MetroHealth System, Case Western Reserve University, Cleveland, OH; Brain Stimulation and Robotics Laboratory (D.E.), Burke Neurological Institute; Department of Telemedicine and Virtual Rehabilitation (D.P.), Burke Medical Research Institute, White Plains, NY; Abilities Research Center (D.P.), Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Clinical Neurosciences (K.A.), University of California, San Diego, La Jolla; Brooks Rehabilitation Clinical Research Center (K.N.), Brooks Rehabilitation, Jacksonville, FL; Department of Physical Medicine and Rehabilitation (E.J.R.), Northwestern University, Chicago, IL; Department of Neurology (D.L.T.), University of Washington, Seattle; Departments of Health Science and Research (M.L.W.) and Public Health Sciences (W.Z.), Medical University of South Carolina, Charleston; Department of Physical Medicine and Rehabilitation (R.Z.), Spaulding Rehabilitation Hospital, Massachusetts General Hospital, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Department of Neurology (J. Spilker, J.P.B.), University of Cincinnati, OH; Department of Rehabilitation Medicine (S.L.W.), Division of Physical Therapy Education, Emory University, Atlanta, GA; Atlanta VA Health Care System (S.L.W.), Center for Visual and Neurocognitive Rehabilitation, Decatur, GA; and NINDS (S.J.), NIH, Bethesda, MD.

Go to [Neurology.org/N](https://www.neurology.org/N) for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

## Glossary

FDA = US Food and Drug Administration; FM = Fugl-Meyer; mRS = modified Rankin Scale; NIHSS = NIH Stroke Scale; NINDS = National Institute of Neurological Disorders and Stroke; tPA = tissue plasminogen activator.

## Clinical Trial

Clinicaltrials.gov identifier: NCT02360488.

## Classification of Evidence

This study provides Class III evidence that for patients >90 days poststroke with persistent arm motor deficits, intensive arm motor therapy improved mRS in a substantial fraction (31.2%) of patients.

US Food and Drug Administration (FDA) approval of a new therapy requires evidence for clinical benefit to the patient,<sup>1</sup> using a clinical end point that measures how a patient feels, functions, or survives,<sup>2,3</sup> where function is ability to perform daily activities.<sup>4</sup> Trials of acute stroke therapies often assess benefit using the modified Rankin Scale (mRS), which covers functional outcomes,<sup>5</sup> is categorized by the WHO International Classification of Function (ICF) as a measure of activities limitations<sup>6,7</sup> (previously called “disability”<sup>8</sup>), and is accepted by the FDA as the primary end point for acute stroke trials.<sup>5</sup> Indeed, the mRS is included with the definition of stroke disability codeveloped by the FDA.<sup>9</sup>

In contrast, trials of stroke recovery therapies often assess benefit using measures categorized as loss of body structure/function (previously called “impairment”<sup>8</sup>), such as the Fugl-Meyer (FM) motor scale, and often do not even measure the mRS.<sup>10–13</sup> The relationship between improved body structure/function (e.g., FM scale) and gains in measures of activities limitations (e.g., mRS) is not always evident,<sup>6,14–17</sup> but a better understanding of the relationship between these 2 dimensions could be useful to emerging stroke recovery therapeutics.<sup>18</sup>

This issue was addressed by examining results from a trial of intensive rehabilitation therapy targeting the arm that reported body structure/function gains (FM score),<sup>19</sup> here hypothesizing that intensive rehabilitation therapy also improves activities limitations (mRS scores). To further probe this issue, mRS gains were explored in relation to improvements in body structure/function, both at the summary level (change in total FM score) and at the level of specific motor impairments.

## Methods

### Study Summary

This report provides a novel post hoc analysis of outcomes data from a prior 11-site, assessor-blind study,<sup>19</sup> conducted in the NIH StrokeNet clinical trials network,<sup>20,21</sup> which provided intensive arm motor therapy to 124 adult patients who had a stroke 4–36 weeks prior to enrollment and had persistence of

arm motor deficits, a common<sup>22</sup> and often devastating<sup>6,23,24</sup> consequence of stroke.

Participants were serially evaluated over 1 week at baseline, then approximately 1 week later were randomized to receive 6 weeks of intensive therapy, either in the home using tele-rehabilitation or in the clinic, 70 min/d, 6 d/wk. The therapy approach was based on an upper-extremity task-specific training manual<sup>25</sup> and the Accelerated Skill Acquisition Program.<sup>26</sup> Therapy was supervised by a licensed occupational therapist or physical therapist, included arm exercises and functional training, and was matched in intensity, duration, and frequency across the 2 treatment groups. Therapists performing outcome assessments underwent online training and formal certification on the FM<sup>27</sup> and mRS<sup>28</sup> scales. Both patient groups had a stable motor examination over 1 week at baseline and showed clinically and statistically significant gains on the primary endpoint: change in FM score from baseline to 30 days posttreatment (7.9–8.4 points on this 66-point scale, for which the minimal clinically important difference is 5.25 points).<sup>29</sup> Telerehabilitation was found to be noninferior compared to in-clinic therapy. Given that behavioral gains were near-identical across groups, data from the 2 groups are combined in the current analysis.

### Standard Protocol Approvals, Registrations, and Patient Consents

Ethics approval was obtained from the local institutional review board and written informed consent was obtained from all enrollees. Data from this study are listed on Clinicaltrials.gov (NCT02360488).

### Statistics

The purpose of the current analysis is to examine treatment effects on a secondary outcome measure, the mRS, and to determine whether patients who showed a treatment-related change in mRS differ from those who did not with respect to changes in body structure/function, both at the summary level (change in total FM score) and at the level of specific motor impairments (individual FM subscores). The population of interest consists of patients who were enrolled >90 days poststroke, a time when spontaneous motor recovery after

**Table 1** Patient Characteristics

Characteristics	Values
<b>N</b>	77
<b>Age, y</b>	62.0 ± 13.1
<b>Percent right-handed</b>	90.9
<b>Days poststroke at study entry (range)</b>	160 ± 48 (93–252)
<b>Stroke subtype</b>	
Ischemic	85.7
Intracerebral hemorrhage	14.3
<b>Percent female</b>	29.9
<b>Race/ethnicity</b>	
Asian	10.4
Black	23.4
White	64.9
Unknown	1.3
Hispanic	2.6
<b>Geriatric Depression Scale</b>	3.6 ± 3.0
<b>Montreal Cognitive Assessment</b>	26 (22–27.5)
<b>Paretic side R</b>	50.6
<b>Baseline NIHSS score</b>	3 (2–4)
<b>Baseline motor Fugl-Meyer score</b>	40.6 ± 8.3
<b>Change in motor Fugl-Meyer score from baseline to 30 days posttherapy</b>	7.5 ± 5.8
<b>Modified Rankin Scale score, baseline</b>	3 (2–3)
<b>Modified Rankin Scale score, 30 days posttherapy</b>	2 (2–3)
<b>Modified Rankin Scale score ≤2 at baseline</b>	46.8
<b>Modified Rankin Scale score ≤2 at 30 days posttherapy</b>	66.2

Values are mean ± SD, median (interquartile range), or %.

stroke is largely complete,<sup>30–32</sup> and so observed behavioral gains are more likely attributable to the intervention rather than spontaneous motor recovery.

Analyses were 2-tailed, used  $\alpha = 0.05$ , did not adjust for covariates, and were calculated using JMP v13.2.0 (SAS, Cary, NC). To examine within-patient changes over time, paired *t* tests were used when data were normally distributed or could be transformed; otherwise, the Wilcoxon signed rank test was used; nonparametric statistics were used for analyses of FM scores. When comparing differences between those who had improvements on mRS and those who did not, the *t* test was used for continuous variables when data were normally distributed or could be transformed; otherwise, the Wilcoxon rank

sum test was used.  $\chi^2$  testing was used to compare categorical variables. Logistic regression was used when mRS score change status (changed or not) was the dependent variable and linear regression was used when the change in mRS score was the dependent variable. The de-identified publicly available National Institute of Neurological Disorders and Stroke (NINDS) tissue plasminogen activator (tPA) trial<sup>33</sup> mRS outcome data were downloaded and evaluated for comparison with current findings.<sup>34</sup>

The FM motor score for the arm is the sum of 33 assessments of specific motor impairment, each scored as 0 (not done at all), 1 (partly done), or 2 (faultless performance),<sup>27,35</sup> with higher values indicating better arm motor status. After examining mRS score change status in relation to change in the total FM score, mRS change status was then examined in relation to each of the 33 specific motor impairments assessed by the FM; no correction was made for multiple comparisons, as the goal was to identify which specific impairment improvements are most related to gains in global function from baseline to 30 days posttherapy.

### Classification of Evidence

The 2 primary research questions were (1) What is the effect of intensive rehabilitation on the mRS, a measure of activities limitation? and (2) What are the specific changes in body structure/function (motor impairment) that are most related to mRS gains? This study provides level III evidence because these questions were addressed analyzing data from a controlled trial, where the control was an active comparator: in-home telerehabilitation vs in-clinic therapy, matched in intensity, duration, and frequency across the 2 randomly assigned treatment groups.

### Data Availability


The complete de-identified study data, as well as the study protocol and statistical analysis plan, are available indefinitely through the NINDS Archived Clinical Research Datasets website.

## Results

### Patients

Of the 124 patients in the clinical trial of intensive rehabilitation therapy, 85 were enrolled >90 days (range 93–252) after stroke onset. Of these, 8 dropped out prior to measurement of mRS score change; the main reasons were the patient was lost to follow-up, was removed from the study by local physician, or withdrew consent. This left 77 patients who are the primary focus of this report (table 1) and who did not differ ( $p > 0.05$ ) from the 8 who dropped out in age, days from stroke to randomization, baseline Geriatric Depression Scale score, Montreal Cognitive Assessment score, FM motor score, NIHSS score, or mRS score. These 77 patients were on average 5.3 months poststroke at study entry, mostly had stroke that was ischemic in origin, had mild cognitive and

**Figure 1** Intensive Arm Therapy Improves Modified Rankin Scale (mRS) Scores



The number of patients at each mRS level is shown at baseline (at study entry, 160 ± 48 days poststroke) and 30 days after end of a 6-week course of intense rehabilitation therapy (approximately 12 weeks postbaseline). Intense rehabilitation therapy targeting the arm was associated with activities gains as measured by the mRS. (A) At baseline, median mRS score was 3 (2–3), decreasing to 2 (2–3) at 30 days posttherapy ( $p < 0.0001$ ). This decrease reflects 24 patients (31.2%) with an mRS score decrease, 50 patients (64.9%) with no change, and 3 (3.9%) patients with an mRS score increase. (B) The proportion of patients with mRS score  $\leq 2$  increased from 46.8% at baseline to 66.2% at 30 days posttherapy ( $*p = 0.015$ ).

moderate motor deficits, and were compliant with 97.2% of the assigned therapy sessions. There were 3 serious adverse events, all unrelated to study procedures. Nonserious adverse events considered reasonably or definitely related to study procedures occurred in 9 patients and consisted of fatigue or arm/shoulder pain; none interrupted study therapy. Weight did not change from baseline to 30 days posttherapy (median change, 0 pounds,  $p = 0.75$ ). Baseline FM score was  $40.6 \pm 8.3$  points (mean ± SD) and increased by  $7.5 \pm 5.8$  points at 30 days posttherapy ( $p < 0.0001$ ).

### Does Intense Rehabilitation Therapy Improve Activities Limitations, Measured as a Decrease in mRS Score?

At baseline (160 ± 48 days poststroke), median mRS score was 3 (interquartile range, 2–3), with scores ranging from 1 to 4. At 30 days posttherapy (approximately 12 weeks postbaseline), median mRS decreased to 2 (2–3) (range 1–4), a significant change ( $p < 0.0001$ , figure 1A). Similarly, the proportion of patients with mRS score  $\leq 2$ , a metric commonly used in acute stroke studies,<sup>5</sup> increased from 46.8% at baseline to 66.2% at 30 days posttherapy ( $p = 0.015$ , figure 1B). These findings (table 2) are accounted for by 24 patients (31.2%) with an mRS score decrease (5 with a 2-point drop and 19 with a 1-point drop), 50 patients (64.9%) with no change, and 3 (3.9%) patients with an mRS score increase (all 1 point). The proportion of patients showing an mRS score decrease was similar ( $p = 0.07$ ) in the telerehabilitation group (17/43, 39.5%) and the in-clinic therapy group (7/34, 20.6%). Also, the proportion of patients showing an mRS score decrease was similar ( $p = 0.73$ ) in patients with ischemic stroke (20/66, 30.3%) compared to patients with intracerebral hemorrhage (4/11, 36.4%).

### How Do Patients Who Did Show Improvement in Activities Limitations (mRS) Differ From Those Who Did Not?

The 24 patients who had an mRS score decrease from baseline to 30 days posttherapy, compared with the 53 patients who did not, had higher baseline mRS score (3 [3–3.75] vs 2 [2–3],  $p = 0.0002$ ). The 2 groups did not differ, however, in the number of study-provided treatment sessions ( $p = 0.70$ ) or number of hours of any rehabilitation therapy received outside of study procedures ( $p = 0.92$ ). In addition, the likelihood of an mRS score decrease was not related to the number of days poststroke at study entry (range odds ratio 1.49, 95% confidence interval 0.3–7.3,  $p = 0.62$ ).

When patients with mRS gains, vs those without, were examined in relation to improvements in body structure/function, the 2 groups did not differ in the change in the total FM motor score over the same period ( $7.9 \pm 6.4$  vs  $7.3 \pm 5.6$  points,  $p = 0.63$ ). Furthermore, change in total FM score was not related to change in mRS score ( $p = 0.25$ ) or to the likelihood of an mRS score decrease ( $p = 0.70$ ).

### Specific Motor Impairments That Improved in Relation to mRS Score Decrease

Although the change in total FM score change did not differ when comparing patients with mRS gains vs those without, there were nonetheless differences between these 2 groups in the specific motor impairments that improved over time.

Change in the specific motor impairments measured by each of the 33 FM subscores is listed for the 24 patients who had an mRS score decrease from baseline to 30 days posttherapy (table 3) and for the 53 patients who did not (table 4). Some

**Table 2** Change in Modified Rankin Scale (mRS) Score From Baseline to 30 Days Posttherapy

mRS at baseline	mRS 30 days posttherapy			
	1	2	3	4
1	2	1	0	0
2	4	28	1	0
3	3	11	17	1
4	0	2	4	3

For each mRS score level at baseline (160 ± 48 days poststroke), the number of patients is presented at each mRS score level 30 days posttherapy (approximately 12 weeks after baseline).

of these specific motor impairments improved in more than a third of patients, while others improved in fewer than 10% of patients. The motor impairments that improved most often were not the same in the 2 groups.

None of the 33 specific impairments measured by FM subscores improved to an extent that it could, as a single independent variable in bivariate analysis, predict the likelihood of mRS score decrease from baseline to 30 days posttherapy: figure 2 presents the odds ratio relating gains in the 33 specific motor impairments to likelihood of mRS improvement, and in each case, the 95% confidence interval crosses 1, indicating prediction of likelihood of mRS improvement was not significant. However, examining the 4 specific motor impairments with the highest odds ratio (figure 2) in a multiple logistic regression analysis did predict the likelihood of mRS

improvement ( $p = 0.034$ ). These 4 are (1) flexing all fingers at the metacarpophalangeal and interphalangeal joints, (2) full shoulder girdle elevation, (3) no reflex hyperactivity in the arm, and (4) circumduction of the wrist through full range of motion in a smooth manner.

## Discussion

Acute stroke trials often rely on the mRS, a measure of activities limitations that covers functional outcomes.<sup>5</sup> However, stroke recovery trials typically do not measure the mRS<sup>10–13</sup> and instead focus on measures capturing loss of body structure/function (such as the FM scale that covers motor impairments), which have an uncertain relationship to measure of activities limitations.<sup>6,14–17</sup> The current report therefore examined change in mRS scores in patients receiving intense rehabilitation therapy targeting the arm >90 days poststroke, hypothesizing that significant improvements in mRS scores would be seen, and exploring how such improvements are related to improvements in body structure/function. Intense therapy was associated with a significant ( $p < 0.0001$ ) drop in mRS score. In an exploratory analysis, these gains were explained in part by improvement in several specific motor impairments such as finger flexion and wrist circumduction. The results indicate that a 6-week course of intense rehabilitation can improve activities limitations (mRS score) in a substantial fraction of patients with stroke, and suggest that there may be specific motor impairments that underlie mRS improvement that may be evaluated as optimal targets for rehabilitation therapies aiming to improve function in hemiparetic patients.

**Table 3** Change in the Specific Motor Impairments Measured by the 33 Fugl-Meyer (FM) Subscores Among the 24 Patients Whose Modified Rankin Scale (mRS) Score Decreased

FM subscore (specific motor impairment)	Number of patients in whom change in score was:					Patients in whom subscore increased, n (%)
	-2 points	-1 point	0 points	+1 point	+2 points	
13. Pure shoulder flexion 0–90 degrees while maintaining full elbow extension	0	1	10	12	1	13 (54.2)
33. Speed of hand movements	0	0	11	11	2	13 (54.2)
16. Pure shoulder flexion 90–180 degrees while maintaining full elbow extension	0	1	12	9	2	11 (45.8)
20. Repeated dorsiflex/volarflex wrist, elbow at 90 degrees flexion	0	1	12	11	0	11 (45.8)
28. Oppose thumb pad to index finger pad	0	2	11	9	2	11 (45.8)
24. Flex all fingers	0	0	14	10	0	10 (41.7)
30. Grasp with 5 fingers	1	2	11	8	2	10 (41.7)
22. Repeated dorsiflex/volarflex wrist while maintaining full elbow extension	0	1	14	9	0	9 (37.5)
23. Circumduct wrist while maintaining full elbow extension	0	0	15	9	0	9 (37.5)

Continued

**Table 3** Change in the Specific Motor Impairments Measured by the 33 Fugl-Meyer (FM) Subscores Among the 24 Patients Whose Modified Rankin Scale (mRS) Score Decreased (*continued*)

FM subscore (specific motor impairment)	Number of patients in whom change in score was:					Patients in whom subscore increased, n (%)
	-2 points	-1 point	0 points	+1 point	+2 points	
4. Shoulder girdle elevation	0	1	15	8	0	8 (33.3)
14. Forearm supination/pronation, elbow at 90 degrees flexion	0	0	16	8	0	8 (33.3)
15. Abduct shoulder to 90 degrees while maintaining full elbow extension	0	1	15	8	0	8 (33.3)
26. Grasp while extending MCP joints and flexing IP joints	0	3	13	4	4	8 (33.3)
27. Grasp with thumb abduction and full extension of CMC, MCP, and IP joints	1	2	13	5	3	8 (33.3)
3. Shoulder girdle retraction	0	1	16	7	0	7 (29.2)
21. Dorsiflex wrist while maintaining full elbow extension	0	1	16	5	2	7 (29.2)
25. Extend all fingers	0	1	16	7	0	7 (29.2)
29. Grasp with volar surface of thumb and index finger	1	2	14	6	1	7 (29.2)
32. Dysmetria of hand movements	0	0	17	7	0	7 (29.2)
8. Forearm supination	0	1	17	6	0	6 (25)
17. Forearm supination/pronation while maintaining full elbow extension	1	3	14	5	1	6 (25)
19. Dorsiflex wrist, elbow at 90 degrees flexion	0	0	18	5	1	6 (25)
5. Shoulder abduction	0	1	18	5	0	5 (20.8)
12. Position hand on lumbar spine	0	0	19	5	0	5 (20.8)
31. Tremor in hand	0	3	16	5	0	5 (20.8)
6. Shoulder external rotation	0	3	17	4	0	4 (16.7)
18. Biceps, triceps, finger flexor reflexes	1	0	19	1	3	4 (16.7)
7. Elbow flexion	0	2	19	3	0	3 (12.5)
9. Shoulder adduction/internal rotation	0	2	19	3	0	3 (12.5)
10. Elbow extension	0	0	21	3	0	3 (12.5)
1. Biceps/finger flexor reflex	0	0	22	0	2	2 (8.3)
11. Forearm pronation	0	2	20	2	0	2 (8.3)
2. Triceps reflex	0	0	24	0	0	0 (0)

Abbreviations: CMC = carpometacarpal; IP = interphalangeal; MCP = *metacarpophalangeal*. For the 24 patients whose mRS score decreased from baseline to 30 days posttherapy, the change for each of the specific motor impairments measured by the 33 FM subscores is presented. The specific motor impairments are presented in rank order according to percentage of patients showing improvement. The number in front of the specific impairment reflects the order of testing in the FM scale.

In patients an average of 5.3 months poststroke, 6 weeks of intensive arm rehabilitation was associated with a decrease in median mRS score, from 3 to 2 ( $p < 0.0001$ ; figure 1A), and an increase in the proportion of patients with final mRS score  $\leq 2$  from 46.8% to 66.2% (figure 1B). The absence of an inactive comparator group makes it difficult to know whether some component of the observed mRS change is due to spontaneous recovery rather than study-provided therapy. That the main

driver of mRS gains was study therapy, rather than spontaneous recovery, is suggested by the absence of a relationship between likelihood of mRS gain and time poststroke ( $p = 0.62$ ); a significant negative relationship might be expected if spontaneous recovery was a substantial contributor to mRS gains given that spontaneous recovery declines with time poststroke. Also, an mRS improvement in 31.2% of patients compares favorably with literature reports of patient trajectories during similar time

**Table 4** Change in the Specific Motor Impairments Measured by the 33 Fugl-Meyer (FM) Subscores Among the 53 Patients Whose Modified Rankin Scale (mRS) Score Did Not Decrease

FM subscore (specific motor impairment)	Number of patients in whom change in score was:					Patients in whom subscore increased, n (%)
	-2 points	-1 point	0 points	+1 point	+2 points	
13. Pure shoulder flexion 0-90 degrees while maintaining full elbow extension	0	0	29	22	2	24 (45.3)
21. Dorsiflex wrist while maintaining full elbow extension	1	1	27	19	5	24 (45.3)
33. Speed of hand movements	1	2	26	22	2	24 (45.3)
30. Grasp with 5 fingers	0	3	28	20	2	22 (41.5)
22. Repeated dorsiflex/volarflex wrist while maintaining full elbow extension	0	4	28	20	1	21 (39.6)
27. Grasp with thumb abduction and full extension of CMC, MCP, and IP joints	0	3	29	16	5	21 (39.6)
28. Oppose thumb pad to index finger pad	0	3	29	19	2	21 (39.6)
29. Grasp with volar surface of thumb and index finger	0	0	32	17	4	21 (39.6)
15. Abduct shoulder to 90 degrees while maintaining full elbow extension	0	4	29	15	5	20 (37.7)
26. Grasp while extending MCP joints and flexing IP joints	1	5	27	15	5	20 (37.7)
12. Position hand on lumbar spine	0	2	32	17	2	19 (35.8)
16. Pure shoulder flexion 90-180 degrees while maintaining full elbow extension	0	2	33	17	1	18 (34)
20. Repeated dorsiflex/volarflex wrist, elbow at 90 degrees flexion	0	1	34	18	0	18 (34)
3. Shoulder girdle retraction	0	4	32	17	0	17 (32.1)
8. Forearm supination	0	4	32	17	0	17 (32.1)
11. Forearm pronation	0	5	33	14	1	15 (28.3)
10. Elbow extension	0	2	37	14	0	14 (26.4)
23. Circumduct wrist while maintaining full elbow extension	0	6	33	13	1	14 (26.4)
5. Shoulder abduction	0	1	39	13	0	13 (24.5)
14. Forearm supination/pronation, elbow at 90 degrees flexion	0	2	38	13	0	13 (24.5)
19. Dorsiflex wrist, elbow at 90 degrees flexion	0	1	40	11	1	12 (22.6)
24. Flex all fingers	0	0	41	12	0	12 (22.6)
32. Dysmetria of hand movements	0	9	32	11	1	12 (22.6)
7. Elbow flexion	0	2	40	11	0	11 (20.8)
9. Shoulder adduction/internal rotation	0	3	39	11	0	11 (20.8)
31. Tremor in hand	0	3	29	11	0	11 (20.8)
4. Shoulder girdle elevation	0	4	39	10	0	10 (18.9)
6. Shoulder external rotation	1	3	39	10	0	10 (18.9)
25. Extend all fingers	0	3	40	10	0	10 (18.9)
17. Forearm supination/pronation while maintaining full elbow extension	0	2	42	8	1	9 (17)
2. Triceps reflex	0	0	50	0	3	3 (5.7)

Continued



**Table 4** Change in the Specific Motor Impairments Measured by the 33 Fugl-Meyer (FM) Subscores Among the 53 Patients Whose Modified Rankin Scale (mRS) Score Did Not Decrease (*continued*)


FM subscore (specific motor impairment)	Number of patients in whom change in score was:					Patients in whom subscore increased, n (%)
	-2 points	-1 point	0 points	+1 point	+2 points	
1. Biceps/finger flexor reflex	0	0	51	0	2	2 (3.8)
18. Biceps, triceps, finger flexor reflexes	1	0	51	0	1	1 (1.9)

Abbreviations: CMC = carpometacarpal; IP = interphalangeal; MCP = *metacarpophalangeal*. For the 53 patients whose mRS score did not decrease from baseline to 30 days posttherapy, the change for each of the specific motor impairments measured by the 33 FM subscores is presented. The specific motor impairments are presented in rank order according to percentage of patients showing improvement. The number in front of the specific impairment reflects the order of testing in the FM scale.

periods: most data suggest that spontaneous functional improvement is uncommon after 3 months poststroke.<sup>32</sup> For example, functional recovery was completed  $\leq 12.5$  weeks poststroke in 95% of Copenhagen Study enrollees<sup>31</sup> and mRS score improved from day 90 to month 6 poststroke in only 18.0% of 471 surviving NINDS tPA study enrollees,<sup>34</sup> although 25% of Oxford Vascular Study enrollees with 3-month mRS  $\geq 1$  showed mRS improvement by 1 year.<sup>36</sup> Moreover, in the current study, only 3.9% of enrollees experienced mRS score worsening, which also compares favorably with literature reports: 11.5% declined in the NINDS tPA study,<sup>34</sup> 20.2% declined in the Oxford Vascular

Study, and Ullberg et al.<sup>37</sup> found that 16.3% of 28,683 patients who were activities of daily living-independent at 3 months deteriorated to activities of daily living dependency at 12 months poststroke. A patient-level meta-analysis of 1,822 patients<sup>38</sup> found that from 3 to 12 months poststroke, the number of mRS improvements was counterbalanced with the number of mRS declines. Whether 6 weeks of intense rehabilitation therapy initiated >90 days poststroke contributes to functional improvement or prevents functional decline, or both, can be more clearly understood in future studies that include an inactive comparator group.

**Figure 2** Odds Ratio for Modified Rankin Scale (mRS) Score Improvement in Relation to Gains in Specific Motor Impairments



The forest plot displays the odds ratio (95% confidence interval) for mRS decrease in relation to improvement in each of the specific motor impairments measured by the 33 FM subscores; no data are presented for the second subscore (triceps reflex) because calculation of the odds ratio was unstable due to 74 of 77 patients showing no change over time. CMC = carpometacarpal; IP = interphalangeal; MCP = metacarpophalangeal.

To understand the finding that mRS improved in 31.2% of patients, patients who showed a treatment-related change in mRS were contrasted with those who did not. Patients with, vs those without, an mRS score decrease from baseline to 30 days posttherapy did not differ in the change in total FM score over the same time period. In addition, change in total FM score was not related to change in mRS score or to the likelihood of an mRS score decrease. On the one hand, degree of weakness is a key influence on functional outcomes after stroke,<sup>39–41</sup> with cross-sectional mRS scores showing a significant albeit incomplete relationship with motor status.<sup>23,42</sup> On the other hand, a limited relationship exists across WHO ICF dimensions, such as loss of body function/structure (here measured using change in total FM score) and activities limitations (here measured using change in mRS score),<sup>6,14–17</sup> although exceptions have been suggested.<sup>43</sup> The absence of a relationship between change in total FM score and change in mRS score in the current study may reflect the fact that numerous factors have a greater influence on outcome as one moves from body function/structure to activity limitations,<sup>6</sup> or that the FM captures numerous arm impairments and only some of these are relevant to functional gains as measured by the mRS.

The latter possibility was explored by comparing specific motor impairments between patients who showed a treatment-related change in mRS and patients who did not. Thus while change in total FM score was not related to likelihood of mRS score decrease, change in specific motor impairments did show a link to likelihood of mRS score decrease. Whereas no single specific motor impairment improved to an extent that significantly predicted likelihood of mRS improvement, combining the 4 strongest predictors did. Although based on an exploratory analysis, these findings suggest that certain specific motor impairments might be optimal targets of therapies that aim to improve the mRS in hemiparetic patients who are >90 days poststroke. For example, therapies that target finger flexion or wrist circumduction might be evaluated to see if they increase the likelihood of functional gains; lack of hyperactive deep tendon reflexes is a marker of a healthy nervous system and not likely a treatment target per se.

This report has several limitations. The sample size of 77 patients is modest. Evaluation of the 33 specific motor impairments from the FM scale did not correct for multiple comparisons and is an exploratory analysis. Across 11 US sites, only 29.9% of enrollees were female. Six of the patients with mRS improvement had a baseline mRS score of 4 (table 2), indicating inability to walk without assistance, and so the contribution of gait improvement is unclear for a therapy that targeted the arm.

Among patients >90 days poststroke, intensive arm rehabilitation was associated with mRS improvement in 31% of patients. In patients with, vs those without, a treatment-related mRS gain, the change in total FM score change was not different. However, patients with a treatment-related mRS gain were more likely to show improvement in specific motor

impairments, such as finger flexion and wrist circumduction. This suggests that not all motor impairments have the same effect on functional outcome, and therefore improvement in motor impairments that have a stronger link to function could be targeted as a useful component of a broader rehabilitation therapy strategy. These findings emphasize the importance of understanding the relationship between changes in activities limitations and loss of body structure/function after stroke. This would be aided by including both types of measures in acute stroke trials and in stroke recovery trials, as has been recommended.<sup>44</sup> Such knowledge would foster a more cohesive system for understanding the benefit of stroke therapeutics, from acute to recovery targets.

## Study Funding

The study was supported by the Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) as well as NINDS (U01 NS091951), K24 HD074722, and T32 AR047752.

## Disclosure

Dr. Cramer is a consultant for AbbVie, Constant Therapeutics, MicroTransponder, Neuroolutions, SanBio, Fujifilm Toyama Chemical Co., and TRCare; V. Le, for TRCare. No other authors have any disclosures to report. Go to [Neurology.org/N](http://Neurology.org/N) for full disclosures.

## Publication History

Received by *Neurology* August 7, 2020. Accepted in final form December 23, 2020.

## Appendix Authors

Name	Location	Contribution
Steven C. Cramer, MD	UCLA	Study design, data collection, data analysis, manuscript preparation
Vu Le, MS	UC Irvine	Study design, data collection, data analysis, manuscript preparation
Jeffrey L. Saver, MD	UCLA	Data analysis, manuscript preparation
Lucy Dodakian, MA, OTR/L	UC Irvine	Study design, data collection, data analysis, manuscript preparation
Jill See, PT, MPT	UC Irvine	Study design, data collection, data analysis, manuscript preparation
Renee Augsburger, OTR/L	UC Irvine	Study design, data collection, data analysis, manuscript preparation
Alison McKenzie, DPT, PhD	Chapman University	Study design, data collection, data analysis, manuscript preparation
Robert J. Zhou, BA	UC Irvine	Study design, data collection, data analysis, manuscript preparation

## Appendix (continued)

Name	Location	Contribution
<b>Nina L. Chiu, BS</b>	UC Irvine	Study design, data collection, data analysis, manuscript preparation
<b>Jutta Heckhausen, PhD</b>	UC Irvine	Study design, data collection, data analysis, manuscript preparation
<b>Jessica M. Cassidy, DPT, PhD</b>	UC Irvine	Study design, data collection, data analysis, manuscript preparation
<b>Walt Scacchi, PhD</b>	UC Irvine	Study design, data collection, data analysis, manuscript preparation
<b>Megan Therese Smith, PhD</b>	UC Irvine	Data analysis, manuscript preparation
<b>A.M. Barrett, MD</b>	Kessler Institute	Data collection, manuscript preparation
<b>Jayne Knutson, PhD</b>	Case Western Reserve University	Data collection, manuscript preparation
<b>Dylan Edwards, PhD, PT</b>	Burke Neurological Institute	Data collection, manuscript preparation
<b>David Putrino, PhD, PT</b>	Burke Medical Research Institute	Data collection, manuscript preparation
<b>Kunal Agrawal, MD</b>	UC San Diego	Data collection, manuscript preparation
<b>Kenneth Ngo, MD</b>	Brooks Rehabilitation	Data collection, manuscript preparation
<b>Elliot J. Roth, MD</b>	Northwestern University	Data collection, manuscript preparation
<b>David L. Tirschwell, MD</b>	University of Washington	Data collection, manuscript preparation
<b>Michelle L. Woodbury, PhD, OTR/L</b>	Medical University of South Carolina	Data collection, manuscript preparation
<b>Ross Zafonte, DO</b>	Harvard Medical School	Data collection, manuscript preparation
<b>Wenle Zhao, PhD</b>	Medical University of South Carolina	Data collection, data analysis, manuscript preparation
<b>Judith Spilker, BSN, RN</b>	University of Cincinnati	Study design, data collection, manuscript preparation
<b>Steven L. Wolf, PT, PhD</b>	Emory University	Data collection, data analysis, manuscript preparation
<b>Joseph P. Broderick, MD</b>	University of Cincinnati	Study design, data collection, data analysis, manuscript preparation
<b>Scott Janis, PhD</b>	National Institutes of Health	Study design, manuscript preparation

## References

1. Katz R. FDA: evidentiary standards for drug development and approval. *NeuroRx* 2004;1:307–316.

2. FDA-NIH Biomarker Working Group. BEST (Biomarkers, Endpoints, and Other Tools). Silver Spring: Food and Drug Administration; 2016. Available at: [ncbi.nlm.nih.gov/books/n/biomarkers/pdf/](https://www.fda.gov/oc/ohrt/biomarkers/)
3. US Department of Health and Human Services, Food and Drug Administration. Guidance for Industry: Expedited Programs for Serious Conditions: Drugs and Biologics. 2017. Available at: [fda.gov/media/86377/download](https://www.fda.gov/media/86377/download). Accessed August 5, 2020.
4. Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. *Stat Med* 2012;31:2973–2984.
5. Broderick JP, Adeoye O, Elm J. Evolution of the modified Rankin Scale and its use in future stroke trials. *Stroke* 2017;48:2007–2012.
6. Winstein CJ, Stein J, Arena R, et al. Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2016;47:e98–e169.
7. Shirley Ryan Ability Lab. Rehabilitation Measures Database. Available at: [sralab.org/rehabilitation-measures/modified-rankin-handicap-scale](https://www.sralab.org/rehabilitation-measures/modified-rankin-handicap-scale). Accessed August 5, 2020.
8. Ustun TB, Chatterji S, Bickenbach J, Kostanjsek N, Schneider M. The International Classification of Functioning, Disability and Health: a new tool for understanding disability and health. *Disabil Rehabil* 2003;25:565–571.
9. Hicks KA, Mahaffey KW, Mehran R, et al. 2017 Cardiovascular and stroke endpoint definitions for clinical trials. *Circulation* 2018;137:961–972.
10. Wolf SL, Winstein CJ, Miller JP, et al. Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke: the EXCITE randomized clinical trial. *JAMA* 2006;296:2095–2104.
11. McCabe J, Monkiewicz M, Holcomb J, Pundik S, Daly JJ. Comparison of robotics, functional electrical stimulation, and motor learning methods for treatment of persistent upper extremity dysfunction after stroke: a randomized controlled trial. *Arch Phys Med Rehabil* 2015;96:981–990.
12. Daly JJ, McCabe JP, Holcomb J, Monkiewicz M, Gansen J, Pundik S. Long-dose intensive therapy is necessary for strong, clinically significant, upper limb functional gains and retained gains in severe/moderate chronic stroke. *Neurorehabil Neural Repair* 2019;33:523–537.
13. Ward NS, Brander F, Kelly K. Intensive upper limb neurorehabilitation in chronic stroke: outcomes from the Queen Square programme. *J Neurol Neurosurg Psychiatry* 2019;90:498–506.
14. Burridge JH, Turk R, Notley SV, Pickering RM, Simpson DM. The relationship between upper limb activity and impairment in post-stroke hemiplegia. *Disabil Rehabil* 2009;31:109–117.
15. Lemmens RJM, Timmermans AAA, Janssen-Potten YJM, Smeets RJEM, Seelen HAM. Valid and reliable instruments for arm-hand assessment at ICF activity level in persons with hemiplegia: a systematic review. *BMC Neurol* 2012;12.
16. Lewthwaite R, Winstein CJ, Lane CJ, et al. Accelerating stroke recovery: body structures and functions, activities, participation, and quality of life outcomes from a large rehabilitation trial. *Neurorehabil Neural Repair* 2018;32:150–165.
17. Roth EJ, Heinemann AW, Lovell LL, Harvey RL, McGuire JR, Diaz S. Impairment and disability: their relation during stroke rehabilitation. *Arch Phys Med Rehabil* 1998;79:329–335.
18. Lin DJ, Finklestein SP, Cramer SC. New directions in treatments targeting stroke recovery. *Stroke* 2018;49:3107–3114.
19. Cramer SC, Dodakian L, Le V, et al. Efficacy of home-based telerehabilitation vs in-clinic therapy for adults after stroke: a randomized clinical trial. *JAMA Neurol* 2019;76:1079–1087.
20. Broderick JP, Palesch YY, Janis LS; National Institutes of Health StrokeNet. The National Institutes of Health StrokeNet: a user's guide. *Stroke* 2016;47:301–303.
21. Cramer SC, Wolf SL, Adams HP, Jr., et al. Stroke recovery and rehabilitation research: issues, opportunities, and the National Institutes of Health StrokeNet. *Stroke* 2017;48:813–819.
22. Rathore S, Hinn A, Cooper L, Tyroler H, Rosamond W. Characterization of incident stroke signs and symptoms: findings from the atherosclerosis risk in communities study. *Stroke* 2002;33:2718–2721.
23. Stewart JC, Cramer SC. Patient-reported measures provide unique insights into motor function after stroke. *Stroke* 2013;44:1111–1116.
24. Wyller TB, Sveen U, Sodring KM, Pettersen AM, Bautz-Holter E. Subjective well-being one year after stroke. *Clin Rehabil* 1997;11:139–145.
25. Lang C, Birkenmeier R. Upper-Extremity Task-specific Training after Stroke or Disability. Bethesda: AOTA Press; 2013.
26. Winstein CJ, Wolf SL, Dromerick AW, et al. Effect of a task-oriented rehabilitation program on upper extremity recovery following motor stroke: the ICARE randomized clinical trial. *JAMA* 2016;315:571–581.
27. See J, Dodakian L, Chou C, et al. A standardized approach to the Fugl-Meyer assessment and its implications for clinical trials. *Neurorehabil Neural Repair* 2013;27:732–741.
28. Saver JL, Filip B, Hamilton S, et al. Improving the reliability of stroke disability grading in clinical trials and clinical practice: the Rankin Focused Assessment (RFA). *Stroke* 2010;41:992–995.
29. Page SJ, Fulk GD, Boyne P. Clinically important differences for the upper-extremity Fugl-Meyer Scale in people with minimal to moderate impairment due to chronic stroke. *Phys Ther* 2012;92:791–798.
30. Nakayama H, Jorgensen H, Raaschou H, Olsen T. Recovery of upper extremity function in stroke patients: the Copenhagen Stroke Study. *Arch Phys Med Rehabil* 1994;75:394–398.

31. Jorgensen H, Nakayama H, Raaschou H, Vive-Larsen J, Stoier M, Olsen T. Outcome and time course of recovery in stroke. Part II: time course of recovery. The Copenhagen Stroke Study. *Arch Phys Med Rehabil* 1995;76:406–412.
32. Rejno A, Nasic S, Bjalkefur K, Bertholds E, Jood K. Changes in functional outcome over five years after stroke. *Brain Behav* 2019;9:e01300.
33. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. *N Engl J Med* 1995; 333:1581–1587.
34. National Institute of Neurological Disorders and Stroke. Archived clinical research datasets. Available at: [ninds.nih.gov/Current-Research/Research-Funded-NINDS/Clinical-Research/Archived-Clinical-Research-Datasets](https://ninds.nih.gov/Current-Research/Research-Funded-NINDS/Clinical-Research/Archived-Clinical-Research-Datasets). Accessed August 5, 2020.
35. Fugl-Meyer A, Jaasko L, Leyman I, Olsson S, Steglind S. The post-stroke hemiplegic patient: a method for evaluation of physical performance. *Scand J Rehabil Med* 1975; 7:13–31.
36. Ganesh A, Luengo-Fernandez R, Wharton RM, et al. Time course of evolution of disability and cause-specific mortality after ischemic stroke: implications for trial design. *J Am Heart Assoc* 2017;6:e005788.
37. Ullberg T, Zia E, Petersson J, Norrving B. Changes in functional outcome over the first year after stroke: an observational study from the Swedish stroke register. *Stroke* 2015;46:389–394.
38. de Havenon A, Tirschwell D, Heitsch L, et al. Variability of the modified Rankin Scale score between day 90 and 1 year after ischemic stroke. *Neurol Clin Pract Epub* 2020 Sep 11.
39. Kwakkel G, Wagenaar RC, Kollen BJ, Lankhorst GJ. Predicting disability in stroke: a critical review of the literature. *Age Ageing* 1996;25:479–489.
40. Shelton F, Volpe B, Reding M. Motor impairment as a predictor of functional recovery and guide to rehabilitation treatment after stroke. *Neurorehabil Neural Repair* 2001; 15:229–237.
41. Weimar C, Ziegler A, Konig IR, Diener HC. Predicting functional outcome and survival after acute ischemic stroke. *J Neurol* 2002;249:888–895.
42. Kongsawasdi S, Klaphajone J, Wivatvongvana P, Watcharasaksilp K. Prognostic factors of functional outcome assessed by using the modified Rankin scale in subacute ischemic stroke. *J Clin Med Res* 2019;11:375–382.
43. Mehrholz J, Pohl M, Platz T, Kugler J, Elsner B. Electromechanical and robot-assisted arm training for improving activities of daily living, arm function, and arm muscle strength after stroke. *Cochrane Database Syst Rev* 2018;9:CD006876.
44. Kwakkel G, Lannin NA, Borschmann K, et al. Standardized measurement of sensorimotor recovery in stroke trials: consensus-based core recommendations from the Stroke Recovery and Rehabilitation Roundtable. *Neurorehabil Neural Repair* 2017; 31:784–792.